Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
- Conditions
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Instituto Nacional de Cirugia Cardiaca, Uruguay
- Target Recruit Count
- 140
- Registration Number
- NCT03807921
- Locations
- 🇺🇾
Instituto Nacional de Cirugia Cardiaca, Montevideo, Uruguay
🇺🇾Centro Cardiovascular Universitario, Montevideo, Uruguay
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-03-19
- Target Recruit Count
- 80
- Registration Number
- NCT03792152
Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Institute for Clinical and Experimental Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03781258
- Locations
- 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Prague 4, Czechia
Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT03747081
- Locations
- 🇮🇷
Alzahra University Hospital, Isfahan, Iran, Islamic Republic of
Anti-thrombotic Monotherapy With the HeartMate 3 LVAS
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Institute for Clinical and Experimental Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT03704220
- Locations
- 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Prague 4, Czechia
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03702582
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University College, London
- Target Recruit Count
- 43
- Registration Number
- NCT03684564
- Locations
- 🇬🇧
Barts and the London Hospitals, Barts Health NHS Trust, London, United Kingdom
🇬🇧Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧University College Hospitals NHS Foundation Trust, London, United Kingdom
Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- PharmEvo Pvt Ltd
- Registration Number
- NCT03673605
- Locations
- 🇵🇰
National Institute of Cardiovascular, Karachi, Sindh, Pakistan
Low INR to Minimize Bleeding With Mechanical Valves Trial
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 2625
- Registration Number
- NCT03636295
- Locations
- 🇳🇱
Erasmus University Medical Centre, Rotterdam, Netherlands
🇧🇷InCor-HCFMUSP, Cerqueira César, São Paulo, Brazil
🇨🇦Hamilton General Hospital, Hamilton, Ontario, Canada
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2021-01-08
- Target Recruit Count
- 402764
- Registration Number
- NCT03596502
- Locations
- 🇨🇦
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.